A clinical trial to study the effects of Unani formulation Habb-ul-Misk with Arq-e-Abresham Alvikhan as an adjuvant therapy for ischemic heart disease

Evaluating the efficacy of Habb-ul-Misk with Arq-e-Abresham Alvikhan as an adjuvant therapy for Iqfari Marad-i-Qalb (Ischemic Heart Disease) a double arm randomized control trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100404

Enrollment

Registered

2026-01-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I259- Chronic ischemic heart disease, unspecified

Interventions

Intervention1: Habb-ul-Misk, Arq-e-Abresham Alvikhan: Group 1: Ingestion of Habb-ul-Misk 250 mg with Arq-e-Abresham Alvikhan 30 ml twice a day after food for 45 days in IHD/CAD participants under

Eligibility

Inclusion criteria

Inclusion criteria: Participants with clinical symptoms like chest pain or dyspnoea or fatigue or palpitation Participants with previous history of IHD under standard treatement protocol Participants with post-angioplasty or post-CABG under standard treatment protocol Cardiac markers - Troponin I, Troponin T, CK-MD with in normal range Post-myocardial infarction Electrocardiogram and echocardiogarm with ischemic changes ECHO - Ejection fraction greater than 40

Exclusion criteria

Exclusion criteria: Age below 31 years and above 60 years Patient with previous history of IHD not under standard treatment protocol Acute Coronary Syndrome Unstable angina Echo - Ejection fraction less than 40 Any other systemic illness Pregnant and lactating women Patients who are not willing for consent

Design outcomes

Primary

Measure	Time frame
Evaluating the efficacy of Habb-ul-Misk with Arq-e-Abresham Alvikhan as an adjuvant therapy in overall cardiac and autonomic function. This will be measured through: Subjective Improvement: Reduction in the severity of angina using the Canadian Cardiovascular Society (CCS) grading and improvement in the New York Heart Association (NYHA) functional classification. Objective Improvement: Electrocardiography (ECG): Improvement in ST-segment and T-wave abnormalities. Echocardiography: Improvement in Left Ventricular Ejection Fraction (LVEF) and reduction in regional wall motion abnormalities. Heart Rate Variability (HRV): Improvement in cardiac autonomic regulation using Time-Domain (SDNN, RMSSD) and Frequency-Domain (LF, HF, LF/HF ratio) parameters.Timepoint: Clinical History: Pre-test & Post-test Baseline - Day 0 and 3rd follow-up - Day 45 New York Heart Association Classification Canadian Cardiovascular Society grading of angina pectoris Non-invasive techniques: Pre-test & Post-test Baseline - Day 0 and 3rd follow-up - Day 45 Electrocardiography Echocardiogram Heart Rate Variability	—

Measure

Time frame

Evaluating the efficacy of Habb-ul-Misk with Arq-e-Abresham Alvikhan as an adjuvant therapy in overall cardiac and autonomic function. This will be measured through: Subjective Improvement: Reduction in the severity of angina using the Canadian Cardiovascular Society (CCS) grading and improvement in the New York Heart Association (NYHA) functional classification. Objective Improvement: Electrocardiography (ECG): Improvement in ST-segment and T-wave abnormalities. Echocardiography: Improvement in Left Ventricular Ejection Fraction (LVEF) and reduction in regional wall motion abnormalities. Heart Rate Variability (HRV): Improvement in cardiac autonomic regulation using Time-Domain (SDNN, RMSSD) and Frequency-Domain (LF, HF, LF/HF ratio) parameters.Timepoint: Clinical History: Pre-test & Post-test Baseline - Day 0 and 3rd follow-up - Day 45 New York Heart Association Classification Canadian Cardiovascular Society grading of angina pectoris Non-invasive techniques: Pre-test & Post-test Baseline - Day 0 and 3rd follow-up - Day 45 Electrocardiography Echocardiogram Heart Rate Variability

—

Secondary

Measure	Time frame
Systemic Safety ProfileTimepoint: Baseline - Day 0 and 3rd Follow-up - Day 45;Quality of LifeTimepoint: Baseline - Day 0, 1st Follow-up - Day 15, 2nd Follow-up - Day 30 and 3rd Follow-up - Day 45	—

Countries

India

Contacts

Public ContactDr Mubasheera Begum

Government Unani Medical College, Chennai

muskaan.m@gmail.com9841620486

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026